N6-methyladenosine methylation in ophthalmic diseases: From mechanisms to potential applications

Bingyan Li; Zicong Wang; Haixiang Zhou; Jingling Zou; Shigeo Yoshida; Yedi Zhou

doi:10.1016/j.heliyon.2023.e23668

N6-methyladenosine methylation in ophthalmic diseases: From mechanisms to potential applications

Heliyon. 2023 Dec 13;10(1):e23668. doi: 10.1016/j.heliyon.2023.e23668. eCollection 2024 Jan 15.

Authors

Bingyan Li^{1

2

3}, Zicong Wang^{1

2

3}, Haixiang Zhou^{1

2

3}, Jingling Zou^{1

2

3}, Shigeo Yoshida⁴, Yedi Zhou^{1

2

3}

Affiliations

¹ Department of Ophthalmology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
² Hunan Clinical Research Center of Ophthalmic Disease, Changsha, Hunan, 410011, China.
³ National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
⁴ Department of Ophthalmology, Kurume University School of Medicine, Kurume, Fukuoka, 830-0011, Japan.

Abstract

N6-methyladenosine (m⁶A) modification, as the most common modification method in eukaryotes, is widely involved in numerous physiological and pathological processes, such as embryonic development, malignancy, immune regulation, and premature aging. Under pathological conditions of ocular diseases, changes in m⁶A modification and its metabolism can be detected in aqueous and vitreous humor. At the same time, an increasing number of studies showed that m⁶A modification is involved in the normal development of eye structures and the occurrence and progress of many ophthalmic diseases, especially ocular neovascular diseases, such as diabetic retinopathy, age-related macular degeneration, and melanoma. In this review, we summarized the latest progress regarding m⁶A modification in ophthalmic diseases, changes in m⁶A modification-related enzymes in various pathological states and their upstream and downstream regulatory networks, provided new prospects for m⁶A modification in ophthalmic diseases and new ideas for clinical diagnosis and treatment.

Keywords: Diabetic retinopathy; Melanoma; Ophthalmic diseases; m6A modification; m6A modification-related enzymes.

Publication types

Review